VPM was invited to join the TBVI (TuBerculosis Vaccine Initiative) Annual Symposium which was held on 29th of January until 31th of January 2019 in Les Diablerets, Switzerland.
From 28. to 29.11.2018, VPM organized a kick off meeting in Johannesburg, South Africa, for a pivotal VPM1002 phase III trial to be conducted in newborn infants in South Africa, Tanzania, Kenya, Uganda and Gabon.
This year's conference topic is "15 Years VPM - from Target to Market". The presentations during the event will address critical factors for successful translational research and development.
First results of the VPM1002BC clinical Phase I/II study will be presented at the international congress of the European Association of Urology 2018 in Copenhagen, Denmark that will take place from 16. to 20.03.2018.
VPM will speak during the 2018 PDA Europe Vaccines conference in Malaga, Spain that will take place from 24. to 25.04.2018.
VPM will speak during the 8th Annual Vaccine World Summit 2018 in Pune India, that will take place from 20. to 21.02.2018.
VPM will be present at the 5th Global Forum on TB Vaccines in New Delhi from February 20-23, 2018.
VPM is going to present on the status of the VPM1002 TB Vaccine at the TBVI symposium in Les Diablerets, Switzerland on 30 January 2018.
VPM will be present at the WHO Consultation on New Tuberculosis Vaccine Research and Development in Geneva, Switzerland from October 3-4, 2017.
VPM will be present at the TRANSLATIONAL MEDICINE 2017 conference in Prague, Czech republic from September 24-26, 2017.